Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study)
Journal of Gastroenterology · 2025-12 · 60 (12) · 1523-1534
DOI: 10.1007/s00535-025-02299-9 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Gastroenterology, online erschienen am 22.09.2025. Verfasst von Katsuyoshi Matsuoka und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center, 564-1, Shimoshizu, Sakura-Shi, C…. Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kissei Pharmaceutical Co., Ltd., EA Pharma Co., Ltd..
Abstract (Originalsprache)
Background
Carotegrast methyl is approved for treating patients with moderately active ulcerative colitis with inadequate response to 5-aminosalicylic acid agents. However, real-world evidence to guide optimal use is limited. This retrospective study aimed to characterise suitable patient profiles, identify biomarkers predictive of carotegrast methyl efficacy, and determine the appropriate timing for treatment evaluation.
Methods
We analysed data from 186 patients enrolled in a phase 3 trial of carotegrast methyl (96 carotegrast methyl, 90 placebo). We assessed biomarkers (leucine-rich α -2 glycoprotein, C-reactive protein, faecal calprotectin, and anti-integrin αvβ6 antibody titres) alongside clinical outcomes and assessed symptom diaries and maintenance therapies.
Results
Low disease activity at baseline (partial Mayo score ≤ 5) was associated with higher remission rates (56.1 vs. 33.3%). Anti-integrin αvβ6 antibody titres of < 44.6 U/mL at baseline predicted higher clinical remission rates (49.1 vs. 26.8%). Symptom improvement was detectable from week 2. Faecal calprotectin correlated with the endoscopic subscore at the end of treatment ( ρ = 0.566); a faecal calprotectin level of < 387.5 µg/g predicted Mayo endoscopic subscore 0/1. Most patients maintained remission with oral 5-aminosalicylic acid alone; the 1-year maintenance rate was 56.5%.
Conclusions
Carotegrast methyl appears most effective in patients with moderately active ulcerative colitis with low disease activity, with week 2 and beyond as an appropriate time point for assessing efficacy. Anti-integrin αvβ6 antibody titre shows promise in predicting response to carotegrast methyl. Faecal calprotectin may serve as a non-invasive surrogate for evaluating endoscopic healing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center, 564-1, Shimoshizu, Sakura-Shi, Chiba, 285-8741, Japan. matsuoka@fk2.so-net.ne.jp.
- Department of Gastroenterology and Medicine, Fukuoka University Hospital, Fukuoka, Japan.
- Department of Internal Medicine for Inflammatory Bowel Disease, University of Toyama, Toyama, Japan.
- Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan.
- Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Förderung
- Kissei Pharmaceutical Co., Ltd.
- EA Pharma Co., Ltd.
Zitieren
APA
Matsuoka, K., Hirai, F., Watanabe, K., Hokari, R., Kobayashi, T., Saruta, M., Nakase, H., Suzuki, T., Yamazaki, G., Hibi, T., Watanabe, M., & Hisamatsu, T. (2025). Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study). Journal of Gastroenterology, 60(12), 1523-1534. https://doi.org/10.1007/s00535-025-02299-9
Vancouver
Matsuoka K, Hirai F, Watanabe K, Hokari R, Kobayashi T, Saruta M, et al. Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study). Journal of Gastroenterology. 2025;60(12):1523-1534. doi:10.1007/s00535-025-02299-9
BibTeX
@article{Matsuoka2025,
author = {Matsuoka, Katsuyoshi and Hirai, Fumihito and Watanabe, Kenji and Hokari, Ryota and Kobayashi, Taku and Saruta, Masayuki and Nakase, Hiroshi and Suzuki, Takahiro and Yamazaki, Gakuto and Hibi, Toshifumi and Watanabe, Mamoru and Hisamatsu, Tadakazu},
title = {Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study)},
journal = {Journal of Gastroenterology},
year = {2025},
volume = {60},
number = {12},
pages = {1523--1534},
doi = {10.1007/s00535-025-02299-9}
}
EUVIMED